

32. (Three Times Amended) A composition consisting of a recombinant modified Ankara (MVA) vector into which are inserted DNA sequences coding for (i) the early E6 polypeptide of a papillomavirus; (ii) the early E7 polypeptide of a papillomavirus; (iii) the late L1 polypeptide of a papillomavirus; and (iv) the late L2 polypeptide of a papillomavirus; each of said DNA sequences being placed under the control of the elements necessary for its expression in a host cell or organism.

43. (Amended) The composition of claim 32, wherein said recombinant MVA vector is provided in combination with a pharmaceutically acceptable carrier.

44. (Three Times Amended) A composition consisting of a recombinant modified Ankara (MVA) vector into which are inserted DNA sequences coding for (i) the early E6 polypeptide of a papillomavirus; (ii) the early E7 polypeptide of a papillomavirus; (iii) the late L1 polypeptide of a papillomavirus; and (iv) the late L2 polypeptide of a papillomavirus; and (v) a polypeptide having an immunostimulatory activity;

wherein each of said DNA sequences is placed under the control of the elements necessary for its expression in a host cell or organism and wherein said polypeptide having an immunostimulatory activity is selected from the group consisting of interleukin-2, interleukin-7, the co-adhesion molecule B7.1 and the co-adhesion molecule B7.2.

52. (Twice Amended) The composition of claim 44, wherein said recombinant MVA vector is provided in combination with a pharmaceutically acceptable carrier.

65. (Twice Amended) A composition consisting of a recombinant modified Ankara (MVA) vector into which are inserted DNA sequences coding for (i) the E6 polypeptide of a papillomavirus (ii) the E7 polypeptide of a papillomavirus and (iii) a polypeptide having an immunostimulatory activity; each of said DNA sequences being placed under the control of the elements necessary for its expression in a host cell or organism and wherein said polypeptide having an immunostimulatory activity is selected from the group consisting of interleukin-2, interleukin-7, the co-adhesion molecule B7.1 and the co-adhesion molecule B7.2.

78. (Amended) The composition of claim 65, wherein said recombinant MVA vector is provided in combination with a pharmaceutically acceptable carrier.